PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease.
Lu C, Yan HH, Zhang CY, Chen SY, Li YS, Wang BC, Xu CR, Tu HY, Zhong WZ, Zhou Q, Zhang XC, Wu YL, Feng WN, Jiang GM, Yang JJ.
Lu C, et al. Among authors: zhang xc.
Clin Lung Cancer. 2024 Dec 4:S1525-7304(24)00265-1. doi: 10.1016/j.cllc.2024.12.002. Online ahead of print.
Clin Lung Cancer. 2024.
PMID: 39721825